市场调查报告书
商品编码
1173206
特应性皮炎治疗药物全球市场规模,份额和行业趋势分析报告:按给药途径,类别(生物製剂,神经钙蛋白抑製剂,皮质类固醇,PDE4抑製剂)区域展望和预测2022-2028Global Atopic Dermatitis Drugs Market Size, Share & Industry Trends Analysis Report By Route of Administration, By Class (Biologics, Calcineurin Inhibitors, Corticosteroids, PDE4 Inhibitors), By Regional Outlook and Forecast, 2022 - 2028 |
到 2028 年,特应性皮炎疗法的全球市场规模预计将达到 220 亿美元,预测期内復合年增长率为 9.2%。
特应性皮炎可在任何年龄发病,但通常首先出现在儿童时期,其严重程度随时间而变化。 在 1 岁以下的儿童中,身体的许多部位都会受到影响。 随着孩子年龄的增长,内侧膝盖和肘部是最常受影响的区域。 在成年人中,它最常见于手脚。
抓挠患处会加重病情,抓挠者更容易发生皮肤感染。 特应性皮炎通常会导致哮喘和花粉热。 治疗包括避免加重疾病的事物、定期洗澡和使用保湿霜、出现症状时使用类固醇霜以及减少瘙痒的药物。
羊毛衣物、肥皂、香水、灰尘、氯气和香烟烟雾是经常加重症状的一些因素。 光疗可能对某些人有帮助。 当其他治疗无效时,可使用类固醇药片和基于钙调神经磷酸□抑製剂的洗剂。 如果有细菌感染,应给予抗生素(口服或外用)。 只有在检测到食物过敏时才需要饮食治疗。
COVID-19 影响分析
冠状病毒正在全球范围内给人们的生活带来问题,扰乱从社交互动到医疗保健再到我们看待外部世界的方式等方方面面。 由于大流行,所有行业的利润和产量都在下降。 然而,由于患者就诊不规律,特应性皮炎治疗市场预计将受到严重影响。 即使在这种情况下,远程皮肤病学仍在继续发展,因为绝大多数患者无需看医生就能接受常规和后续护理。
市场增长因素
对生物製剂的需求不断增长
皮肤病的治疗,尤其是特应性皮炎,已经通过在皮肤病学中使用生物製剂而发生了转变。 生物製剂能够很好地应对特应性皮炎并改善整体生活质量。 因此,现在对特应性皮炎的生物治疗的需求不断增长。 这种模式可能会在未来几年继续下去。 目前只有一种生物製剂被批准用于治疗特应性皮炎。 许多产品目前正在进行二期临床试验,并可能在不久的将来获得批准。
特应性皮炎患病率上升
预计推动特应性皮炎药物市场的主要因素是全球特应性皮炎患者数量的增加。 许多人患有特应性皮炎,预计未来几年这一数字还会增加。 地理条件、气候条件、社会经济地位、生活方式、年龄、性别、遗传和个人行为都会影响世界范围内特应性皮炎的患病率。 特应性皮炎必须与日常过敏有关。
市场製约因素
外用类固醇的副作用
少于 4 週的局部类固醇治疗通常没有风险或问题。 长期使用局部类固醇和频繁短剂量使用高刺激性类固醇会引起问题。 一个主要问题是长期使用强效类固醇。 温和的局部类固醇几乎没有副作用。 外用类固醇具有局部和全身副作用。 系统性是影响整个个体的问题,局部性是影响皮肤特定区域的问题。
班级展望
根据类别,特应性皮炎治疗市场分为皮质类固醇、神经钙蛋白抑製剂、PDE4 抑製剂、生物製剂等。 到 2021 年,皮质类固醇部分在特应性皮炎治疗市场中占有重要的收入份额。 可的松、氢化可的松和泼尼松等皮质类固醇药物可以成功治疗炎症性肠病、皮疹和哮喘等许多病症。
管理路线展望
根据给药途径,特应性皮炎药物市场分为外用剂、注射剂和口服剂。 注射剂将在 2021 年的特应性皮炎药物市场中占据最大的收入份额。 这是由于像 dupilumab 这样的注射剂越来越受欢迎。 Tofacitinib 和 ruxolitinib 是其他正在临床试验中研究的可注射生物製剂。 在不久的将来,生物製剂有望改变 AD 治疗格局。
区域展望
按地区分析了北美、欧洲、亚太地区和 LAMEA 的特应性皮炎治疗市场。 2021 年,北美地区将以最高的收入份额引领特应性皮炎治疗市场。 成熟的研发基础设施和友好的报销规则是该地区持续占据主导地位的两个关键因素。 此外,随着该领域研究的快速发展,监管和报销环境也在不断变化。
收购是市场进入者采取的主要策略。 根据 Cardinal Matrix 中的分析,Pfizer和Novartis AG在特应性皮炎药物市场处于领先地位。 AbbVie, Inc.、Sanofi SA 和 Regeneron Pharmaceuticals Inc. 等公司是特应性皮炎治疗市场的一些领先创新者。
The Global Atopic Dermatitis Drugs Market size is expected to reach $22 billion by 2028, rising at a market growth of 9.2% CAGR during the forecast period.
Eczema, commonly referred to as atopic dermatitis, is a skin ailment that affects the skin and results in itching, dryness, and inflammation. The illness has a potential for chronicity and occasionally flares up and spreads. Drugs for atopic dermatitis, such as atopic eczema steroids, are utilized to treat eczema, lessen itching, and treat other atopic dermatitis-related disorders.
Atopic dermatitis patients run the risk of acquiring asthma, hay fever, and food allergies. Regular moisturizing and other skin care practices help reduce itching and stop future outbreaks. Medicated lotions or ointments may also be used during treatment. It causes skin that is scratchy, red, swollen, and cracked. The damaged sites may leak a clear fluid that thickens over time.
Although the disorder can strike at any age, it usually first manifests in childhood and varies in severity throughout time. Much of the body may be impacted in youngsters under the age of one year. The areas on the inside of the knees and elbows are most frequently affected as kids age. Adults are more frequently afflicted in the hands and feet.
Scratching the affected regions makes the symptoms worse, and individuals who are scratching have a higher chance of developing skin infections. Atopic dermatitis frequently leads to the development of asthma or hay fever. Avoiding things that aggravate the illness, regular bathing followed by the use of moisturizing cream, using steroid creams when flare-ups happen, and drugs to relieve itching are all part of the treatment.
Wool garments, soaps, fragrances, dust, chlorine, and cigarette smoke are a few things that frequently aggravate it. Some people may benefit from phototherapy. If other treatments are ineffective, steroid tablets or lotions based on calcineurin inhibitors may occasionally be employed. If a bacterial infection manifests, antibiotics (by mouth or topically) could be required. Only if food allergies are detected are dietary modifications required.
COVID-19 Impact Analysis
The coronavirus is still creating trouble in people's lives on a worldwide scale, disrupting everything from social interactions to how they seek medical care and see the outside world. Every industry has experienced a profit or output decrease as a result of the pandemic epidemic. However, the market for treating atopic dermatitis has anticipated a substantial impact because of the irregularity of hospital visits by patients. Teledermatology has grown during the crisis when the majority of patients continue to receive generalized care and/or additional consultative therapies without seeing a doctor in person.
Market Growth Factors
Growing Demand For Biologics
The treatment of dermatological disorders, particularly atopic dermatitis, has changed as a result of the use of biologic drugs in dermatology. Biologics have demonstrated a good response to atopic dermatitis, improving the overall quality of life. As a result, there is now a greater demand for biologic treatments for atopic dermatitis. In the upcoming several years, this pattern is probably going to continue. For the time being, only one biologic product has been authorized for the treatment of atopic dermatitis. Many more are currently through phase II clinical studies and will probably be approved soon.
Rising Prevalence Of Atopic Dermatitis
The increasing prevalence of atopic dermatitis medications around the world is anticipated to be the main factor driving the market for atopic dermatitis medications. A large number of people suffer with atopic dermatitis which is expected to rise even more in upcoming years. Geographical location, climatic circumstances, socioeconomic level, lifestyle, age, gender, inheritance, and individual behaviors all have an impact on the prevalence of dermatological problems around the world. An individual with atopic dermatitis must deal with allergies on a daily basis.
Market Restraining Factors
Side Effects Of Topical Steroids
Topical steroid treatments lasting fewer than four weeks are often risk-free and trouble-free. Long-term topical steroid use or frequent repetition of short doses of harsher steroids may cause issues. The primary issue is the prolonged usage of potent steroids. Mild topical steroids rarely have side effects. Topical steroids may have local or systemic side effects. Systemic refers to an issue that affects the entire individual, whereas local refers to that particular area of skin.
Class Outlook
Based on class, the atopic dermatitis drugs market is segmented into corticosteroids, calcineurin inhibitors, PDE4 inhibitors, biologics and others. In 2021, the corticosteroids segment acquired a substantial revenue share in the atopic dermatitis drugs market. Many conditions, such as inflammatory bowel disease, rashes, and asthma, can be successfully treated with corticosteroid medications, such as cortisone, hydrocortisone, and prednisone.
Route Of Administration Outlook
On the basis of route of administration, the atopic dermatitis drugs market is fragmented into topical, injectable and oral. In 2021, the injectable segment held the largest revenue share in the atopic dermatitis drugs market. This is due to the rising popularity of injectable drugs like Dupilumab. Tofacitinib and ruxolitinib are other injectable biologics being studied in clinical trials. In the near future, biologics are anticipated to alter the therapy landscape for AD.
Regional Outlook
Region wise, the atopic dermatitis drugs market is analyzed across North America, Europe, Asia Pacific and LAMEA. In 2021, the North America region led the atopic dermatitis drugs market by generating the highest revenue share. The availability of a well-established R&D infrastructure and kind reimbursement rules are two major factors contributing to the region's sustained dominance. Additionally, the regulatory and reimbursement environment is constantly changing to keep up with the rapid advancement of research in this field.
The major strategies followed by the market participants are Acquisitions. Based on the Analysis presented in the Cardinal matrix; Pfizer, Inc. and Novartis AG are the forerunners in the Atopic Dermatitis Drugs Market. Companies such as AbbVie, Inc., Sanofi SA, Regeneron Pharmaceuticals Inc. are some of the key innovators in Atopic Dermatitis Drugs Market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer Inc., Sanofi SA, AbbVie Inc., Galderma S.A., Eli Lilly and Company, Leo Pharma A/S, Regeneron Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Novartis AG, and Incyte Corporation.
Recent Strategies Deployed in Atopic Dermatitis Drugs Market
Mergers and Acquisitions:
Oct-2022: Incyte completed the acquisition of Villaris Therapeutics, an asset-centric biopharmaceutical company. This acquisition would complement Incyte's current portfolio, providing Incyte the opportunity to improve treatment options for people with vitiligo, that leverage the expertise established in the dermatology space.
Jun-2022: Pfizer took over ReViral, a privately held, clinical-stage Biopharmaceutical Company. This acquisition further demonstrates Pfizer's commitment to advancing pioneering science both through its in-house expertise and work with leading, innovative companies - with the aim to deliver breakthroughs to patients suffering from severe infectious diseases.
Mar-2022: Pfizer completed the acquisition of Arena Pharmaceuticals, an American biopharmaceutical company. Through this acquisition, Pfizer would add the impressive experience and pipeline of Arena Pharmaceuticals to Pfizer's Inflammation & Immunology therapeutic area, helping the company further its purpose of developing breakthroughs to change the lives of those with immuno-inflammatory diseases.
Jan-2022: Galderma took over ALASTIN Skincare, a specialty aesthetics company. This acquisition aimed at enhancing Galderma's integrated dermatology platform with a comprehensive collection of scientifically-approved products for daily skincare regimens and peri-procedural use. Also, the acquisition would underscore Galderma's commitment to being the partner of choice for aesthetic professionals.
Dec-2021: AbbVie took over Soliton, a medical device company. The acquisition would complement Allergan Aesthetics' portfolio of non-invasive body contouring treatments to include a proven treatment for the appearance of cellulite.
Nov-2021: Sanofi completed the acquisition of Translate Bio, a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases. The acquisition support Sanofi's mRNA Center of Excellence, which plans to explore the potential of enhanced mRNA vaccines & other key areas that includes immunology, oncology, and rare diseases.
Nov-2021: Sanofi took over Kadmon Holdings, which operates as a biopharmaceutical company. This acquisition would strengthen the expansion & growth of the general medicines portfolio.
Jul-2019: LEO Pharma completed the acquisition of Bayer. LEO Pharma advances significantly towards its goal of helping 125 million patients by 2025. With this acquisition, the LEO considerably improve its size in key markets like Austria, Brazil, and South Africa - underlining its ambition to become a global leader in medical dermatology.
Approvals and Trials:
Oct-2022: LEO Pharma got European approval for Adtralza, a drug to treat moderate-to-severe AD in adolescents. The approval would address LEO's relentless commitment to bringing the latest treatment options for those living with atopic dermatitis. This approval enables LEO to address the unmet needs of a broader patient population as it looks forwards to work with key stakeholders across the Europe region.
Jun-2022: Sanofi got FDA approval for Dupixent, a biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood. The approval would enable the availability of Dupixent for young people with the disease.
Jan-2022: Pfizer got FDA approval for CIBINQO, an oral, once-daily, Janus kinase 1 (JAK1) inhibitor. CIBINQO would offer the treatment of adults living with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products. CIBINQO would provide an important latest oral option that would help those who have yet to find relief.
Jan-2022: AbbVie got FDA approval for RINVOQ, a once-daily oral option that can significantly enhance the debilitating itch & skin symptoms of atopic dermatitis. Through this acquisition, AbbVie would continue its efforts to enhance care in this disease state & other chronic, immune-mediated conditions.
Dec-2021: Leo Pharma got FDA approval for Adbry, an eczema drug. The injected antibody drug would address adults and older who don't get proper relief from topical prescription therapies. Adbry would signify important progress in LEO's aim of enhancing the standard of care in medical dermatology.
Sep-2021: Otsuka got FDA approval for Moizerto Ointment, a treatment for atopic dermatitis. Otsuka expects that Moizerto Ointment would serve as the latest treatment option for people having atopic dermatitis in Japan.
Sep-2021: Incyte got FDA approval for Opzelura, a topical JAK inhibitor to treat AD. With this approval, the company looks forward to bringing Opzelura to the patient community and also continuing to explore its potential in other skin diseases.
Market Segments covered in the Report:
By Route of Administration
By Class
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures